Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.
J Clin Oncol · 2026-Feb-20 · PMID 41512237
Figure 1
Figure 1. a) 3-year Progression-Free survival (PFS) in adolescent patients with advanced stage cHL by study arm b) 3-year Progression-Free survival (PFS) in adolescent patients with Stage III cHL by study arm c) 3-year Progression-Free survival (PFS) in adolescent patients with Stage IV cHL by study arm d) 3-year Event-Free Survival by study arm, where events on N-AVD were due to non-protocol chemotherapy prior to progression (n=4); non protocol RT prior to progression (n=1) or progression of disease (n=9). With BV-AVD events were due to non-protocol chemotherapy prior to progression (n=1); non-protocol RT prior to progression (n=1) and progression of disease (n=22) and death (n=1). Note: the 95% CI for the hazard ratio (HR) is two-sided.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T16:57:55+00:00 |